BanuK.ArunMD

Oncology • Houston, TX

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Professor, Oncology, University of Texas MD Anderson Cancer Center at Houston

Join to view full profile

Dr. Arun is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Arun's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Fax+1 713-563-0910

Education & Training

MedStar Health Georgetown UniversityFellowship, Hematology and Medical Oncology, 1994 - 1997
Istanbul University FomClass of 1989

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
OK State Medical License 2020 - 2026
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
TN State Medical License 2023 - 2025
TX State Medical License 1998 - 2025
WA State Medical License 2023 - 2025
AL State Medical License 1997 - 2011
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

US Top 27 Breast Oncologist Forbes, 2017
America's Top Doctors Castle Connolly, 2009-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Join now to see all

Clinical Trials

Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 1, Phase 2
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer Start of enrollment: 2003 Oct 03
Completed
Phase 2
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer Start of enrollment: 2008 Mar 01
Completed
Phase 1
A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer Start of enrollment: 2012 Jan 01
Unknown status
Phase 2
Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer Start of enrollment: 2002 Nov 01
Completed
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer Start of enrollment: 2014 Jan 21
COMPLETED
PHASE2
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer Start of enrollment: 2012 Jun 13
Completed
Phase 2
Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast Start of enrollment: 2018 Jan 30
Completed
Phase 2
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer Start of enrollment: 2020 Jul 28
RECRUITING
PHASE2
Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling Start of enrollment: 2022 Nov 03
RECRUITING
Roles: Principal Investigator, Contact
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics Start of enrollment: 2022 Nov 23
RECRUITING
NA
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Skin cancer risk in patients withmutations.
Lucy J Navsaria, Allen M Haas, Jessica L Corredor, Banu K Arun, Sharon H Giordano
JAAD International. 2024-12-01
1 citations
What do cancer genetic providers want us to know about variant reclassification and recontact that we are not asking? A thematic analysis of open-ended survey responses.
Kerri Brown, Marisel Ponton, Elenita Davidson, Banu Arun, Robert J Volk
Cancer. 2024-11-15
6 citations
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing.
Banu Arun, Fergus J Couch, Jean Abraham, Nadine Tung, Peter A Fasching
British Journal of Cancer. 2024-11-01

Journal Articles

Functional Mechanisms Underlying Pleiotropic Risk Alleles at the 19p13.1 Breast–Ovarian Cancer Susceptibility Locus
Susan M Domchek, Beth Y Karlan, Katherine L Nathanson, Kenneth Offit, Banu K Arun, Andrew Berchuck, Patricia A Ganz, Douglas A Levine, Nature

Lectures

Evaluation for Genetic Risk of Breast Cancer in Mammography Centers
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Non-BRCA hereditary gene mutations and breast cancer phenotype: An ISC-RAM Consortia study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

NCCN Issues Updated Guidance on Genetic Testing for Several CancersNovember 25th, 2024
MD Anderson Research Highlights for August 25, 2021August 25th, 2021
Clinical Challenge: BRCA-Mutant Triple-Negative Breast CancerJune 8th, 2021
Join now to see all

Grant Support

Biomarker Modulation/Cox-2 Inhibitor/Breast CancerNational Cancer Institute2002–2003
An Exploratory Study To Identify Potential Surrogate ENDDivision Of Cancer Prevention And Control1999